Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry

Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):323-7. doi: 10.1016/s0002-9378(99)70207-3.

Abstract

Objective: Our purpose was to review patients with granulosa and theca cell tumors as filed in the Emil Novak Ovarian Tumor Registry.

Study design: Our study was a descriptive, retrospective study of 454 case records.

Results: The reviewed diagnoses were for 97 patients with granulosa cell tumors, 116 with theca cell tumors, and 97 with granulosa-theca cell tumors. The remaining cases (n = 144) were reclassified as "nonspecific" gonadal stromal tumors (n = 61), luteomas of pregnancy (n = 7), and 76 "other" cases. These included poorly differentiated cancer, metastatic cancer, mixed mesodermal tumors, and sarcomas. The tumor-related mortality rate for the 310 patients with granulosa, theca, and granulosa-theca cell tumors was 7% (37.3% for granulosa cell tumors only). The surgical stage of disease was the most significant prognostic factor, with a mortality rate of at least 40%, given that the tumor had spread beyond the ovary.

Conclusion: Because the differential diagnoses of particularly granulosa cell tumors included several conditions with an extremely poor prognosis, an accurate histologic diagnosis is crucial.

MeSH terms

  • Diagnosis, Differential
  • Female
  • Granulosa Cell Tumor / diagnosis*
  • Granulosa Cell Tumor / mortality
  • Granulosa Cell Tumor / pathology
  • Humans
  • Menopause
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / pathology
  • Postmenopause
  • Pregnancy
  • Prognosis
  • Registries
  • Retrospective Studies
  • Survival Rate
  • Thecoma / diagnosis*
  • Thecoma / mortality
  • Thecoma / pathology